Target discovery and validation is a crucial step in drug discovery. Finding a good target in a relevant pathway can be challenging. Especially target deconvolution – the retrospective identification of the molecular targets that underlie observed phenotypic responses – can be a true “needle in the hay stack” problem. Biognosys’ discovery proteomics (HRM-MS™) enables quantification of thousands of proteins per sample from virtually any biological matrix, be that cell culture, tissue or body fluids. This enables the unambiguous identification of significantly regulated proteins in a disease model that can reveal many protein targets for therapeutic exploration. Biognosys has been helping customers in many different therapeutics areas such as oncology, neurology, inflammatory and immunological disorders, cardiovascular and metabolic disorders, respiratory disorders, rare diseases and others.
You are likely to benefit if you are looking to:
- Discover or validate new high-quality protein targets for cancer, neurology, inflammatory, immunology, cardiovascular, respiratory or other diseases